Search Results - david+roberts

5 Results

Sort By:

Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47

Abstract: The National Cancer Institute''s Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CD47-targeting agents as radioprotectants and tumor sensitizers. Radiation therapy not only damages cancer cells, but it also damages healthy...

Published: 4/8/2024 | Inventor(s): David Roberts, Justin Maxhimer, Jeff Isenberg

Keywords(s): CANCER, CD47, Morpholinos, Radioprotective Agents, Radiotherapeutics, Thrombospondin-1 (TSP1), Tumor Sensitizers

Category(s): Collaboration Sought > Licensing

Modulating Chemotherapeutic Cytotoxicity

Abstract: Many chemotherapeutic agents cause significant cytotoxicity to non-cancer ("normal") cells, resulting in undesirable side-effects and often limiting the dose and/or duration of chemotherapy that can be administered to a patient. Investigators at the National Cancer Institute’s Laboratory of Pathology have demonstrated that deficiency or blockade...

Published: 4/8/2024 | Inventor(s): David Roberts, David Soto Pantoja

Keywords(s): CD47, morpholino

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Use of Anti-CD47 Antibodies for the Treatment of Cancer

Abstract: High expression of CD47, a cell surface receptor on several types of cancer cells, has been identified as a ‘don’t eat me signal’ that inhibits their killing by macrophages or NK cells. Conversely, the CD47 antibody B6H12 that blocks SIRPα binding enhances macrophage-dependent clearance of tumors in several mouse models, although others have...

Published: 4/8/2024 | Inventor(s): David Roberts, Sukhbir Kaur, Chengyu Liu

Keywords(s): CD47, Stem Cell

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Methods of preventing tissue ischemia

Abstract: The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize therapeutics targeting vasodialation. Nitric oxide (NO) plays an important role as a major intrinsic vasodilator, and increases blood flow...

Published: 4/8/2024 | Inventor(s): Jeff Isenberg, David Roberts, William Frazier

Keywords(s): CD47, ISCHEMIA, nitric oxide, NO, THROMBOSPONDIN

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Method for Generating Pluripotent and Multipotent Cells

Abstract: Research and clinical applications of induced pluripotent stem (iPS) cells are currently limited by reprogramming methods that may modify the host genome, and therefore be potentially unsafe and problematic for use in basic research, cell-based therapies, and drug-discovery applications. Researchers at the National Cancer Institute’s Laboratory...

Published: 4/8/2024 | Inventor(s): David Roberts, Sukhbir Kaur, Jeff Isenberg

Keywords(s): cell-based therapies, cell-reprogramming, iPS cells

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials